Log in
Enquire now
‌

US Patent 11407750 Derivatives of an FGFR inhibitor

Patent 11407750 was granted and assigned to Incyte on August, 2022 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Incyte
Incyte
0
Current Assignee
Incyte
Incyte
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
114077500
Patent Inventor Names
Ming Tao0
Jason Boer0
Date of Patent
August 9, 2022
0
Patent Application Number
171108750
Date Filed
December 3, 2020
0
Patent Citations
‌
US Patent 10016348 Two-phase composition comprising a fatty acid ester of sugar or a liquid alkyl polyglucoside, with an HLB < 8, and a C
0
‌
US Patent 10040790 Bicyclic heterocycles as FGFR inhibitors
0
‌
US Patent 10131667 Substituted tricyclic compounds as FGFR inhibitors
‌
US Patent 10208024 2-aryl- and 2-heteroaryl-substituted 2-pyridazin-3(2H)-one compounds as inhibitors of FGFR tyrosine kinases
‌
US Patent 10213427 Substituted imidazopyridazines and benzimidazoles as inhibitors of FGFR3
‌
US Patent 10214528 Bicyclic heterocycles as FGFR4 inhibitors
0
‌
US Patent 10251892 Bicyclic heterocycles as FGFR4 inhibitors
‌
US Patent 10308644 Heterocyclic compounds as immunomodulators
...
Patent Citations Received
‌
US Patent 12122767 Bicyclic heterocycles as FGFR inhibitors
0
‌
US Patent 11628162 Methods of treating cancer with an FGFR inhibitor
0
‌
US Patent 11667635 Bicyclic heterocycles as FGFR4 inhibitors
0
‌
US Patent 11840534 Substituted tricyclic compounds as FGFR inhibitors
0
‌
US Patent 11939331 Tricyclic heterocycles as FGFR inhibitors
0
‌
US Patent 12012409 Bicyclic heterocycles as FGFR inhibitors
0
‌
US Patent 12024517 Salts of an FGFR inhibitor
0
‌
US Patent 12065494 Combination therapy comprising an FGFR inhibitor and a Nectin-4 targeting agent
0
...
Patent Primary Examiner
‌
Charanjit Aulakh
0
CPC Code
‌
A61K 31/519
0
‌
C07D 471/14
0
‌
A61K 31/5377
0
‌
A61P 35/00
0

The present disclosure relates to derivatives (e.g., hydroxyl, keto, glucuronide, sulfonic acid, and deuterated) of a Fibroblast Growth Factor Receptors (FGFR) inhibitor, including methods of preparation thereof, and intermediates in the preparation thereof, which are useful in the treatment of FGFR mediated disease such as cancer.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11407750 Derivatives of an FGFR inhibitor

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.